The document provides an overview of the COVID-19 vaccination status in India, including the vaccination phases initiated in January 2021, the number of doses administered, and the vaccines approved for use. It discusses challenges such as vaccine hesitancy, wastage, and supply shortages, as well as the need for vaccination among children and pregnant women. Additionally, it highlights the ongoing clinical trials for children and the importance of overcoming barriers to ensure widespread vaccination coverage.

1. COVID-19 Vaccination:
Current status and
Challenges
DR. BHUSHAN KAMBLE,
ASST. PROFESSOR, DEPT. OF CM & FM
1

2. Contents
Introduction
Current status of vaccination
COVID-19 Vaccines approved in India
Vaccine sequencing
Vaccination in pregnancy and lactation
Vaccination for children
Challenges in vaccination
2

3. Introduction
Launched on 16th Jan 2021 in phase
wise manner pan-India
Phase-I 1cr HCWs & 1cr FLWs
Co-WIN App developed by UNDP.
Free of cost
COVISHIELD and COVAXIN Vaccine
3
Date Beneficiary
16th Jan 21 Health Care Workers
(HCWs)
1st Feb 21 Front Line Workers
(FLWs)
1st Mar 21 Geriatric population age
>60 years and
Between 45-59 years
with co-morbidities
1st Apr 21 All people ≥45 years
1st May 21 All >18 years of age

4. Current status of COVID-19 VACCINATION
Availability of more vaccines,
Advance visibility of vaccine
availability to States and UTs
Providing them COVID
Vaccines free of cost.(75%)
4
VACCINE
DOSES
(As on 16
August 2021)
SUPPLIED 56,81,14,630
CONSUMPTI
ON
54,22,75,723
BALANCE
AVAILABLE
2,89,47,890
The new phase of universalization of COVID-19
vaccination has commenced from 21st June, 2021.

5. Cumulative Vaccine
Dose Coverage
On 16th August 2021
Total 55,85,834 vaccine doses given on 16th :
1st Dose: 43,18,152
2nd Dose: 12,67,682.
Cumulative vaccine doses 55,14,89,821
1st Dose: 428426418 (31.7%)
2nd Dose: 123063403 (9.1%)
5
Healthcare workers
1st Dose: 103518482nd Dose: 8114959.
Frontline workers
1st Dose: 18283967 2nd Dose: 12226514
People Aged 18-44 Years
1st Dose: 200068334
2nd Dose: 15935853
People Aged ≥ 45 Years
1st Dose: 118223789 2nd Dose: 46231673
. People Aged ≥ 60 Years 1st Dose:
81498480 2nd Dose: 40554404

6. Statewise Covid-19 vaccination status
Five States namely Madhya Pradesh, Gujarat, Rajasthan, Maharashtra and Uttar
Pradesh: have administered more than 1 Crore Cumulative Doses of COVID-19 Vaccine in
the age group 18-44 years.
Highest doses are given by UP (5,74,28,780), Maharashtra(4,91,99,401), Gujrat
(3,98,45,089), Madhypradesh (3,98,45,089) and Rajsthan (3,75,16,981)
Maharashtra and UP are vaccinating daily approx. 10 lakh dosages and GJ, RJ and Bihar
are vaccinating around 5 lakh people.
Telangana: Total vaccination: 1,62,25,901 (1,64,339), 1st dose:1,20,73,758 2nd
dose:41,52,143
6

7. Vaccination Coverage
7

8. COVID-19 Vaccines approved in India
DCGI has given approval for following 5 COVID-19 vaccines for restricted use in
emergency situation till 16th Aug 2021
8
• COVISHIELD
• COVAXIN
Jan
21
Sputnik
V
Apr
21
Moderna
Jun
21
Johnson
&
Johnson
Aug
21

9. COVID-19 Vaccines approved in India
Vaccine
Type of Vaccine No of
doses
Time gap
between 2 dose Vaccine
Efficacy
Effectivene
ss against
Delta
Variant
Covishield Viral Vector 2 12-16 weeks 70.4%
82.4%*
63%
Covaxin Inactivated virus 2 4 weeks 77.8% 65.2%
Sputnik V Viral Vector 2 3 weeks 91.6% 83%
Moderna mRNA 2 4 weeks 94.1% 76%
Johnson &
Johnson
Viral Vector 1 NA 92.4% 71%
9
*At 4 weeks interval
ZyCov-D
DNA
3 ID2856
Corbevax
Bio E
Protein
subunit
2IM28
Novovax
SII
Protein
subunitIM2
1days

10. Children and Vaccination
The development of the COVID-19 vaccine for
children is in the advanced stages of clinical trials
AIIMS has started the second dose trial of
COVAXIN in 2-6 year old Children.
Zydus Cadila's ZyCOV-D has already submitted
data for approval children over 12 to 18 years.
Conducted trial in 50 centers over 28,000
participants and having efficacy of 66.6% against
symptomatic covid
Moderna vaccine already got emergency use
authorization in USA for 12 to 17 years children
and claimed full protection.
10

11. COVID vaccination for pregnant & lactating mothers
DCGI didn’t give license for Pregnant and lactating mother women due to lack of
trial data.
FIGO, RCOG and FOGSI emphasized vaccination these women despite of limited
availability of data as the risk of getting COVID-19 in pregnancy and its resulting
morbidity is much more than the theoretical risks from the vaccine
Supported by interim recommendation of WHO for use of Covishield vaccine
(ChAdOx1-S) during pregnancy and lactation.
NTAGI, MoHFW approved the vaccination against COVID-19 on 19th May for all
lactating mother and for pregnant women on 2nd July 2021.
 Pregnant women can get Covishield, Covaxin or Sputnik V any time during
pregnancy
If already infected with COVID during pregnancy then she can get vaccine after
delivery.
Till 30 July only 2.3 lakh pregnant women received their Jab. TN, AP, Odisha, MP,
Karala and Karnataka are leading.
11

12. Challenges in COVID Vaccination
COVID
Vaccination
Vaccine
Hesitancy
Vaccine
Wastage
Vaccine
Shortage
Online
Registration
Crowd
Manageme
nt
Effect on
RI
12
 Many states such as JH (37.3%), CG(30.2%), TN(15.5%)
J&K (10.8%) and MP(10.7%) reported much higher
wastage than national average (6.3%)
 Due to vaccine supply shortage many beneficiaries could
not receive their 2nd Dose on time
 Frequent change in policy and update in Co-Win portal.
 Diversions from Vaccine sequencing at many places
 Fear of derailing other Immunisation Programmes
 Vaccine hesitancy reduces vaccine uptake and
compromises herd immunity

13. Vaccine Hesitancy and solutions
Vaccine hesitancy refers to delaying or refusing vaccines despite the availability of vaccine services.
Concerns about vaccine safety, adverse effects, toxicity, Perceptions of low risk , worry about unforeseen future
negative effects or lack of information and support
Possible ways to overcome: Awareness programmes, Dialogue-based interventions, CSR Activities, Training
healthcare professionals, Partner with diverse stakeholders
 WHO Based increasing vaccination model
At the heart of this model is motivation
to be vaccinated. Motivation can be captured by
concepts like readiness, willingness, or intention
13

14. Upcoming Challenges in Covid Vaccination
COVID-19 vaccine breakthrough infections
Variants of Concern: Delta Plus(K417N)
 Vaccine Escape
Duration of protection: 3months to 8 months
Booster doses
14

15. 16